These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 23807661)
21. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer. Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Toyokawa T; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K Anticancer Res; 2014 Jul; 34(7):3753-8. PubMed ID: 24982398 [TBL] [Abstract][Full Text] [Related]
22. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401 [TBL] [Abstract][Full Text] [Related]
23. Node-extranodal soft tissue stage based on extranodal metastasis is associated with poor prognosis of patients with gastric cancer. Jiang N; Deng JY; Ding XW; Ke B; Liu N; Liang H J Surg Res; 2014 Nov; 192(1):90-7. PubMed ID: 24953988 [TBL] [Abstract][Full Text] [Related]
24. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. Marrelli D; Roviello F; De Stefano A; Fotia G; Giliberto C; Garosi L; Pinto E J Am Coll Surg; 2004 Jan; 198(1):51-8. PubMed ID: 14698311 [TBL] [Abstract][Full Text] [Related]
25. [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer]. Zhu YB; Ge SH; Zhang LH; Wang XH; Xing XF; DU H; Hu Y; Li YA; Jia YN; Lin Y; Fan B; Ji JF Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):161-4. PubMed ID: 22368025 [TBL] [Abstract][Full Text] [Related]
26. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. Ishigami S; Natsugoe S; Hokita S; Che X; Tokuda K; Nakajo A; Iwashige H; Tokushige M; Watanabe T; Takao S; Aikou T J Clin Gastroenterol; 2001 Jan; 32(1):41-4. PubMed ID: 11154168 [TBL] [Abstract][Full Text] [Related]
27. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491 [TBL] [Abstract][Full Text] [Related]
28. Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: prognostic value in invasive urothelial carcinoma of the bladder. Ahmadi H; Djaladat H; Cai J; Miranda G; Daneshmand S Urol Oncol; 2014 Jul; 32(5):648-56. PubMed ID: 24680660 [TBL] [Abstract][Full Text] [Related]
29. Early detection of recurrence after endoscopic treatment for early gastric cancer. Sohn YJ; Jang JS; Choi SR; Kwon HC; Jung GJ; Kim MC; Jeong JS Scand J Gastroenterol; 2009; 44(9):1109-14. PubMed ID: 19593687 [TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer. Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733 [TBL] [Abstract][Full Text] [Related]
31. The prognostic value of detecting symptomatic or asymptomatic recurrence in patients with gastric cancer after a curative gastrectomy. Bilici A; Salman T; Oven Ustaalioglu BB; Unek T; Seker M; Aliustaoglu M; Gezen C; Unek T; Yavuzer D; Unlu M; Gumus M; Yilmaz U J Surg Res; 2013 Mar; 180(1):e1-9. PubMed ID: 22520575 [TBL] [Abstract][Full Text] [Related]
32. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients. Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063 [TBL] [Abstract][Full Text] [Related]
33. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Kodera Y; Yamamura Y; Torii A; Uesaka K; Hirai T; Yasui K; Morimoto T; Kato T; Kito T Am J Gastroenterol; 1996 Jan; 91(1):49-53. PubMed ID: 8561143 [TBL] [Abstract][Full Text] [Related]
34. Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: study on 166 cases and suggestion for new therapy. Zhang YH; Li Y; Chen C; Peng CW Hepatogastroenterology; 2009; 56(96):1750-4. PubMed ID: 20214231 [TBL] [Abstract][Full Text] [Related]
35. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361 [TBL] [Abstract][Full Text] [Related]
36. Elevation of preoperative s-CEA concentration in stage IIA colorectal cancer can also be a high risk factor for stage II patients. Kim CW; Yoon YS; Park IJ; Lim SB; Yu CS; Kim JC Ann Surg Oncol; 2013 Sep; 20(9):2914-20. PubMed ID: 23760586 [TBL] [Abstract][Full Text] [Related]
37. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Yakabe T; Nakafusa Y; Sumi K; Miyoshi A; Kitajima Y; Sato S; Noshiro H; Miyazaki K Ann Surg Oncol; 2010 Sep; 17(9):2349-56. PubMed ID: 20217258 [TBL] [Abstract][Full Text] [Related]
38. Surgical resection of stage IV gastric cancer and prognosis. Yamashita K; Sakuramoto S; Kikuchi S; Katada N; Kobayashi N; Watanabe M Anticancer Res; 2007; 27(6C):4381-6. PubMed ID: 18214048 [TBL] [Abstract][Full Text] [Related]
39. CA19-9 is a significant prognostic marker of patients with stage III gastric cancer. Kambara Y; Miyake H; Nagai H; Yoshioka Y; Shibata K; Asai S; Yuasa N Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1918-1924. PubMed ID: 32814681 [TBL] [Abstract][Full Text] [Related]
40. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]